Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Receptor, ErbB-2"" wg kryterium: Temat


Tytuł :
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Autorzy :
Harbeck N; Breast Center, Department of OB & GYN and CCC Munich, LMU University Hospital, Munich, Germany. Electronic address: .
Rastogi P; University of Pittsburgh/UPMC, NSABP Foundation, Pittsburgh, USA.
Martin M; Hospital General Universitario Gregorio Marañon, Universidad Complutense, CIBERONC, GEICAM, Madrid, Spain.
Tolaney SM; Dana-Farber Cancer Institute, Boston, USA.
Shao ZM; Fudan University Shanghai Cancer Center, Shanghai, China.
Fasching PA; University Hospital Erlangen, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Huang CS; National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Jaliffe GG; Grupo Medico Camino S.C., Mexico City, Mexico.
Tryakin A; N.N.Blokhin Russian Cancer Research Center, Moscow, Russia.
Goetz MP; Mayo Clinic, Rochester, USA.
Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco, San Francisco, USA.
Senkus E; Department of Oncology & Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Testa L; Instituto D'Or de Pesquisa e Ensino (IDOR), Sao Paulo, Brazil.
Andersson M; Rigshospitalet, Copenhagen, Denmark.
Tamura K; National Cancer Center Hospital, Tokyo, Japan.
Del Mastro L; IRCSS Ospedale Policlinico San Martino, UO Breast Unit, Genoa, Italy; Università di Genova, Department of Internal Medicine and Medical Specialties (DIM), Genoa, Italy.
Steger GG; Medical University of Vienna, Vienna, Austria.
Kreipe H; Medizinische Hochschule Hannover, Hannover, Germany.
Hegg R; Clin. Pesq. e Centro São Paulo, São Paulo, Brazil.
Sohn J; Yonsei Cancer Center, Seoul, Korea.
Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy; Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
Cortés J; International Breast Cancer Center (IBCC), Madrid & Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain.
Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.
André V; Eli Lilly and Company, Indianapolis, USA.
Wei R; Eli Lilly and Company, Indianapolis, USA.
Barriga S; Eli Lilly and Company, Indianapolis, USA.
Sherwood S; Eli Lilly and Company, Indianapolis, USA.
Forrester T; Eli Lilly and Company, Indianapolis, USA.
Munoz M; Eli Lilly and Company, Indianapolis, USA.
Shahir A; Eli Lilly and Company, Indianapolis, USA.
San Antonio B; Eli Lilly and Company, Indianapolis, USA.
Nabinger SC; Eli Lilly and Company, Indianapolis, USA.
Toi M; Kyoto University Hospital, Kyoto, Japan.
Johnston SRD; Royal Marsden NHS Foundation Trust, London, UK.
O'Shaughnessy J; Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, USA.
Pokaż więcej
Corporate Authors :
monarchE Committee Members
Źródło :
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Dec; Vol. 32 (12), pp. 1571-1581. Date of Electronic Publication: 2021 Oct 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms*/drug therapy
Receptor, ErbB-2*
Aminopyridines ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Benzimidazoles ; Chemotherapy, Adjuvant ; Disease-Free Survival ; Female ; Humans ; Ki-67 Antigen ; Neoplasm Recurrence, Local/drug therapy
Czasopismo naukowe
Tytuł :
HER2 overexpression is a putative diagnostic and prognostic biomarker for late-stage colorectal cancer in North African patients.
Autorzy :
Abdul Razzaq EA; Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Venkatachalam T; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Bajbouj K; Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.
Rahmani M; Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Mahdami A; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Rawat S; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.
Mansuri N; Department of Pathology, University of Turku, Finland.
Alhashemi H; Department of surgery NCI, Sabratha, Libya.
Hamoudi RA; Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Sharjah Institute for Medical Research, University of Sharjah, Sharjah, United Arab Emirates.; Division of Surgery and Interventional Science, University College London, London, United Kingdom.
Bendardaf R; Clinical Sciences Department, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Oncology Unit, University Hospital Sharjah, Sharjah, United Arab Emirates.
Pokaż więcej
Źródło :
The Libyan journal of medicine [Libyan J Med] 2021 Dec; Vol. 16 (1), pp. 1955462.
Typ publikacji :
Journal Article
MeSH Terms :
Colorectal Neoplasms*/diagnosis
Receptor, ErbB-2*/genetics
Biomarkers, Tumor/genetics ; Humans ; Immunohistochemistry ; Prognosis
Czasopismo naukowe
Tytuł :
Design, synthesis, HER2 inhibition and anticancer evaluation of new substituted 1,5-dihydro-4,1-benzoxazepines.
Autorzy :
Cruz-López O; Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Granada, Spain.; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, Spain.
Ner M; Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Granada, Spain.
Nerín-Fonz F; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweeden.
Jiménez-Martínez Y; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, Spain.; Biopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.; Excellence Research Unit 'Modeling Nature' (MNat), Department of Human Anatomy and Embryology, University of Granada, Granada, Spain.
Araripe D; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweeden.
Marchal JA; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, Spain.; Biopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.; Excellence Research Unit 'Modeling Nature' (MNat), Department of Human Anatomy and Embryology, University of Granada, Granada, Spain.
Boulaiz H; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, Spain.; Biopathology and Medicine Regenerative Institute, University of Granada, Granada, Spain.; Excellence Research Unit 'Modeling Nature' (MNat), Department of Human Anatomy and Embryology, University of Granada, Granada, Spain.
Gutiérrez-de-Terán H; Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweeden.
Campos JM; Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Granada, Spain.; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, Spain.
Conejo-García A; Department of Medicinal and Organic Chemistry, Faculty of Pharmacy, University of Granada, Granada, Spain.; Biosanitary Institute of Granada (ibs.GRANADA), SAS-University of Granada, Granada, Spain.
Pokaż więcej
Źródło :
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2021 Dec; Vol. 36 (1), pp. 1553-1563.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Design*
Antineoplastic Agents/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Receptor, ErbB-2/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Receptor, ErbB-2/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Tytuł :
Quantitatively mapping the interaction of HER2 and EGFR on cell membranes with peptide probes.
Autorzy :
Yan Q; State Key Laboratory of Polymer Physics and Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, P. R. China.
Cai M; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .
Jing Y; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .
Li H; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .; University of Science and Technology of China, Hefei, Anhui 230027, China.
Xu H; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .
Sun J; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .
Gao J; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .
Wang H; State Key Laboratory of Electroanalytical Chemistry, Research Center of Biomembranomics, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, 130022, China. .; University of Science and Technology of China, Hefei, Anhui 230027, China.; Laboratory for Marine Biology and Biotechnology, Qing Dao National Laboratory for Marine Science and Technology, Wenhai Road, Aoshanwei, Jimo, Qingdao, Shandong, 266237, China.
Pokaż więcej
Źródło :
Nanoscale [Nanoscale] 2021 Oct 28; Vol. 13 (41), pp. 17629-17637. Date of Electronic Publication: 2021 Oct 28.
Typ publikacji :
Journal Article
MeSH Terms :
Peptides*
Receptor, ErbB-2*/genetics
Cell Differentiation ; Cell Line, Tumor ; Cell Membrane ; Cell Proliferation ; ErbB Receptors/genetics ; Humans
Czasopismo naukowe
Tytuł :
Oncogenic potential of human pluripotent stem cell-derived lung organoids with HER2 overexpression.
Autorzy :
Miura A; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Yamada D; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Nakamura M; Precision Health, Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo, Japan.
Tomida S; Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
Shimizu D; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Jiang Y; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Takao T; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Yamamoto H; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Suzawa K; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Shien K; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Yamane M; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Sakaguchi M; Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Toyooka S; Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Takarada T; Department of Regenerative Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Oct 15; Vol. 149 (8), pp. 1593-1604. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinogenesis*
Gene Expression Regulation, Neoplastic*
Adenocarcinoma of Lung/*pathology
Induced Pluripotent Stem Cells/*pathology
Lung Neoplasms/*pathology
Organoids/*pathology
Receptor, ErbB-2/*metabolism
Adenocarcinoma of Lung/genetics ; Adenocarcinoma of Lung/metabolism ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Differentiation ; Humans ; Induced Pluripotent Stem Cells/metabolism ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Organoids/metabolism ; Receptor, ErbB-2/genetics ; Transcriptome ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Human induced pluripotent stem cell-derived platelets loaded with lapatinib effectively target HER2+ breast cancer metastasis to the brain.
Autorzy :
Bhan A; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA. .
Ansari K; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.; Celcuity LLC, Minneapolis, MN, 55446, USA.
Chen MY; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
Jandial R; Division of Neurosurgery, Beckman Research Institute, City of Hope Medical Center, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 Oct 15; Vol. 11 (1), pp. 16866. Date of Electronic Publication: 2021 Oct 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Brain Neoplasms/*drug therapy
Breast Neoplasms/*drug therapy
Induced Pluripotent Stem Cells/*drug effects
Lapatinib/*pharmacology
Neoplasm Metastasis/*pathology
Receptor, ErbB-2/*drug effects
Animals ; Antineoplastic Agents/pharmacology ; Brain Neoplasms/secondary ; Breast Neoplasms/pathology ; Drug Carriers/pharmacology ; Humans ; Induced Pluripotent Stem Cells/cytology ; Mice, Inbred NOD ; Mice, SCID ; Quinazolines/pharmacology ; Receptor, ErbB-2/metabolism
Czasopismo naukowe
Tytuł :
Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
Autorzy :
Antolín S; Department of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
García-Caballero L; Department of Morphological Sciences, School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain. .
Reboredo C; Department of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
Molina A; Department of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
Mosquera J; Department of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
Vázquez-Boquete Á; Department of Pathology, Santiago de Compostela University Hospital Complex, Santiago de Compostela, Spain.
Gallego R; Department of Morphological Sciences, School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain.
Santiago MP; Department of Pathology, A Coruña University Hospital Complex, A Coruña, Spain.
Concha Á; Department of Pathology, A Coruña University Hospital Complex, A Coruña, Spain.
Pérez E; Department of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
Calvo L; Department of Medical Oncology, A Coruña University Hospital Complex, A Coruña, Spain.
García-Caballero T; Department of Morphological Sciences, School of Medicine and Dentistry, Santiago de Compostela University, Santiago de Compostela, Spain.; Department of Pathology, Santiago de Compostela University Hospital Complex, Santiago de Compostela, Spain.
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Oct; Vol. 479 (4), pp. 853-857. Date of Electronic Publication: 2021 May 01.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Breast Neoplasms/*genetics
Receptor, ErbB-2/*genetics
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Pharmacological ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology ; Female ; Gene Amplification/genetics ; Humans ; In Situ Hybridization, Fluorescence/methods ; Middle Aged ; Neoadjuvant Therapy/methods ; Receptor, ErbB-2/drug effects ; Trastuzumab/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Mastering the Use of Novel Anti-HER2 Treatment Options.
Autorzy :
Tarantino P; Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Trapani D; Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.
Curigliano G; Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Pokaż więcej
Źródło :
JCO oncology practice [JCO Oncol Pract] 2021 Oct; Vol. 17 (10), pp. 605-606. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Receptor, ErbB-2*
Trastuzumab
Czasopismo naukowe
Tytuł :
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study.
Autorzy :
Davey MG; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Kerin E; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.
O'Flaherty C; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.
Maher E; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.
Richard V; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.
McAnena P; Department of Surgery, Galway University Hospitals, Galway, Ireland.
McLaughlin RP; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Sweeney KJ; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Barry MK; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Malone CM; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Wyns W; Department of Cardiology, Galway University Hospitals, Galway, Ireland.
Soliman O; Department of Cardiology, Galway University Hospitals, Galway, Ireland.
Miller N; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland.
Keane MM; Department of Medical Oncology, Galway University Hospitals, Galway, Ireland.
Lowery AJ; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Kerin MJ; The Lambe Institute for Translational Research, National University of Ireland, Galway, Ireland; Department of Surgery, Galway University Hospitals, Galway, Ireland.
Pokaż więcej
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2021 Oct; Vol. 59, pp. 67-75. Date of Electronic Publication: 2021 Jun 18.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms*/drug therapy
Carcinoma, Ductal, Breast*/drug therapy
Receptor, ErbB-2*
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Prognosis ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Tytuł :
Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor.
Autorzy :
Prawira A; Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
Le TBU; Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
Ho RZW; Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore.
Huynh H; Laboratory of Molecular Endocrinology, Division of Cellular and Molecular Research, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore, 169610, Singapore. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Oct; Vol. 147 (10), pp. 2955-2968. Date of Electronic Publication: 2021 Jun 22.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Carcinoma, Hepatocellular/*drug therapy
Drug Resistance, Neoplasm/*drug effects
Enhancer of Zeste Homolog 2 Protein/*metabolism
Gene Expression Regulation, Neoplastic/*drug effects
Receptor, ErbB-2/*metabolism
Receptor, Fibroblast Growth Factor, Type 1/*antagonists & inhibitors
Animals ; Antibodies, Monoclonal, Humanized/administration & dosage ; Apoptosis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Carcinoma, Hepatocellular/metabolism ; Carcinoma, Hepatocellular/pathology ; Cell Proliferation ; Enhancer of Zeste Homolog 2 Protein/genetics ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/metabolism ; Liver Neoplasms/pathology ; Male ; Mice ; Mice, SCID ; Phenylurea Compounds/administration & dosage ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/administration & dosage ; Receptor, ErbB-2/genetics ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Tytuł :
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance.
Autorzy :
Bose R; From the Division of Oncology, Department of Medicine, and the Siteman Cancer Center, Washington University School of Medicine, St. Louis.
Ma CX; From the Division of Oncology, Department of Medicine, and the Siteman Cancer Center, Washington University School of Medicine, St. Louis.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Sep 23; Vol. 385 (13), pp. 1241-1243.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Mutation*
Breast Neoplasms/*genetics
Protein Kinase Inhibitors/*therapeutic use
Quinolines/*therapeutic use
Receptor, ErbB-2/*genetics
Receptor, ErbB-3/*genetics
Female ; Humans ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/metabolism ; Receptor, ErbB-3/metabolism ; Signal Transduction
Czasopismo naukowe
Tytuł :
HER2-targeted therapies in gastric cancer.
Autorzy :
Zhu Y; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Zhu X; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Wei X; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Tang C; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. Electronic address: .
Zhang W; Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China. Electronic address: .
Pokaż więcej
Źródło :
Biochimica et biophysica acta. Reviews on cancer [Biochim Biophys Acta Rev Cancer] 2021 Aug; Vol. 1876 (1), pp. 188549. Date of Electronic Publication: 2021 Apr 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Immunoconjugates/*therapeutic use
Protein Kinase Inhibitors/*therapeutic use
Receptor, ErbB-2/*antagonists & inhibitors
Stomach Neoplasms/*drug therapy
Animals ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents, Immunological/adverse effects ; Drug Resistance, Neoplasm ; Humans ; Immunoconjugates/adverse effects ; Molecular Targeted Therapy ; Protein Kinase Inhibitors/adverse effects ; Receptor, ErbB-2/immunology ; Receptor, ErbB-2/metabolism ; Signal Transduction ; Stomach Neoplasms/enzymology ; Stomach Neoplasms/immunology
Czasopismo naukowe
Tytuł :
Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Autorzy :
Hurvitz SA; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, California, USA.
Saura C; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.
Oliveira M; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, SOLTI Breast Cancer Cooperative Group, Barcelona, Spain.
Trudeau ME; Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Moy B; Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
Delaloge S; Gustave Roussy, Villejuif, France.
Gradishar W; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Haley B; University of Texas Southwestern, Dallas, Texas, USA.
Ryvo L; Sourasky Medical Center (Ichilov), Tel Aviv, Israel.
Dai MS; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Milovanov V; Tambov Regional Oncology Center, Tambov, Russia.
Alarcón J; Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.
Kalmadi S; Ironwood Cancer and Research Centers, Chandler, Arizona, USA.
Cronemberger E; Centro Regional Integrado de Oncologia, Fortaleza, Ceará, Brazil.
Souza C; Hospital de Câncer de Barretos, Barretos, São Paulo, Brazil.
Landeiro L; Nucleo de Oncologia Da Bahia, Ondina, Bahia, Brazil.
Bose R; Washington University School of Medicine, St Louis, Missouri, USA.
Bebchuk J; Puma Biotechnology, Inc., Los Angeles, California, USA.
Kabbinavar F; Puma Biotechnology, Inc., Los Angeles, California, USA.
Bryce R; Puma Biotechnology, Inc., Los Angeles, California, USA.
Keyvanjah K; Puma Biotechnology, Inc., Los Angeles, California, USA.
Brufsky AM; Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, USA.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2021 Aug; Vol. 26 (8), pp. e1327-e1338. Date of Electronic Publication: 2021 Jun 07.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Breast Neoplasms*/drug therapy
Receptor, ErbB-2*/therapeutic use
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Capecitabine/therapeutic use ; Central Nervous System ; Female ; Humans ; Quinolines ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Trans-(-)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?
Autorzy :
Rattanaburee T; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Tanawattanasuntorn T; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Thongpanchang T; Department of Chemistry and Center of Excellence for Innovation in Chemistry (PERCH-CIC), Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
Tipmanee V; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Graidist P; Department of Biomedical Sciences and Biomedical Engineering, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand.
Pokaż więcej
Źródło :
Molecules (Basel, Switzerland) [Molecules] 2021 Jul 27; Vol. 26 (15). Date of Electronic Publication: 2021 Jul 27.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*metabolism
Antineoplastic Agents/*pharmacology
Breast Neoplasms/*metabolism
Lignans/*metabolism
Lignans/*pharmacology
Piper nigrum/*chemistry
Plant Extracts/*metabolism
Plant Extracts/*pharmacology
Receptor, ErbB-2/*metabolism
Breast Neoplasms/pathology ; Cell Proliferation/drug effects ; Female ; Gene Knockdown Techniques ; Humans ; MCF-7 Cells ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Quinolines/pharmacology ; RNA, Small Interfering/genetics ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/genetics ; Signal Transduction/drug effects ; Signal Transduction/genetics ; Transfection
Czasopismo naukowe
Tytuł :
Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
Autorzy :
Horii R; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan. .; Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, Saitama, 362-0806, Japan. .
Nitta H; Roche Tissue Diagnostics, Tucson, AZ, USA.
Nojima M; Center for Translational Research, The Institute of Medical Science Hospital, The University of Tokyo, Tokyo, Japan.
Maruyama R; Project for Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ueno T; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ito Y; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Ohno S; Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Banks P; Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kanda H; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.; Department of Pathology, Saitama Cancer Center, 780 Komuro, Ina, Kita-adachi-gun, Saitama, 362-0806, Japan.
Akiyama F; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Jul; Vol. 479 (1), pp. 13-21. Date of Electronic Publication: 2021 Jan 26.
Typ publikacji :
Journal Article
MeSH Terms :
Genetic Heterogeneity*
Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*genetics
Breast Neoplasms/*drug therapy
Drug Resistance, Neoplasm/*genetics
Receptor, ErbB-2/*genetics
Trastuzumab/*therapeutic use
Adult ; Aged ; Biomarkers, Tumor/antagonists & inhibitors ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/enzymology ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Female ; Gene Amplification ; Gene Expression Regulation, Neoplastic ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Middle Aged ; Predictive Value of Tests ; Receptor, ErbB-2/antagonists & inhibitors ; Receptor, ErbB-2/metabolism
Czasopismo naukowe
Tytuł :
Circular RNA circ-ERBB2 Elevates the Warburg Effect and Facilitates Triple-Negative Breast Cancer Growth by the MicroRNA 136-5p/Pyruvate Dehydrogenase Kinase 4 Axis.
Autorzy :
Huang Y; Department of Ultrasound Diagnosis, Fuzhou Second Hospital affiliated with Xiamen University, Fuzhou, Fujian, China.
Zheng S; Department of Hepatobiliary Surgery, Fuzhou Second Hospital affiliated with Xiamen University, Fuzhou, Fujian, China.
Lin Y; Department of Ultrasound Diagnosis, Fuzhou Second Hospital affiliated with Xiamen University, Fuzhou, Fujian, China.
Ke L; Department of Ultrasound Diagnosis, Fuzhou Second Hospital affiliated with Xiamen University, Fuzhou, Fujian, China.
Pokaż więcej
Źródło :
Molecular and cellular biology [Mol Cell Biol] 2021 Sep 24; Vol. 41 (10), pp. e0060920. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
MicroRNAs/*genetics
Pyruvate Dehydrogenase Acetyl-Transferring Kinase/*genetics
Receptor, ErbB-2/*genetics
Triple Negative Breast Neoplasms/*genetics
Apoptosis/genetics ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/genetics ; Gene Expression/genetics ; Gene Expression Regulation, Neoplastic/genetics ; Humans ; Protein Kinases/genetics ; Protein Kinases/metabolism ; Pyruvate Dehydrogenase Acetyl-Transferring Kinase/metabolism ; RNA, Circular/genetics ; RNA, Circular/metabolism ; Receptor, ErbB-2/metabolism ; Triple Negative Breast Neoplasms/metabolism ; Warburg Effect, Oncologic
Czasopismo naukowe
Tytuł :
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Autorzy :
Ai X; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.
Song Z; Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No.1 East Banshan Road, Hangzhou, 310022, Zhejiang, China.; Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, No.150 Fucheng Road, Hangzhou, 310000, Zhejiang, China.
Jian H; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.
Zhou Z; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.
Chen Z; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.
Yu Y; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.
Li Z; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.
Lu S; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China. .
Pokaż więcej
Źródło :
BMC cancer [BMC Cancer] 2021 Sep 16; Vol. 21 (1), pp. 1033. Date of Electronic Publication: 2021 Sep 16.
Typ publikacji :
Clinical Trial Protocol; Clinical Trial, Phase II; Journal Article
MeSH Terms :
Acrylamides/*administration & dosage
Aminoquinolines/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Receptor, ErbB-2/*genetics
Thalidomide/*administration & dosage
Acrylamides/adverse effects ; Aminoquinolines/adverse effects ; Angiogenesis Inhibitors/administration & dosage ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; China ; Diarrhea/chemically induced ; Drug Administration Schedule ; Exons ; Humans ; Ikaros Transcription Factor/drug effects ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mutation ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Receptor, ErbB-2/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.
Autorzy :
Javle M; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Borad MJ; Mayo Clinic, Scottsdale, AZ, USA.
Azad NS; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kurzrock R; Moores Cancer Center, University of California San Diego, San Diego, CA, USA.
Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
George B; Medical College of Wisconsin, Milwaukee, WI, USA.
Hainsworth J; Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA.
Meric-Bernstam F; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Swanton C; Francis Crick Institute, London, UK; UCL Hospitals, London, UK.
Sweeney CJ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Friedman CF; Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.
Bose R; Washington University School of Medicine, St Louis, MO, USA.
Spigel DR; Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA.
Wang Y; Genentech, South San Francisco, CA, USA.
Levy J; Genentech, South San Francisco, CA, USA.
Schulze K; Genentech, South San Francisco, CA, USA.
Cuchelkar V; Genentech, South San Francisco, CA, USA.
Patel A; Genentech, South San Francisco, CA, USA.
Burris H; Sarah Cannon Research Institute, Nashville, TN, USA; Tennessee Oncology, Nashville, TN, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Sep; Vol. 22 (9), pp. 1290-1300. Date of Electronic Publication: 2021 Jul 30.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Agents, Immunological/*therapeutic use
Biliary Tract Neoplasms/*drug therapy
Receptor, ErbB-2/*metabolism
Trastuzumab/*therapeutic use
Aged ; Biliary Tract Neoplasms/metabolism ; Biliary Tract Neoplasms/pathology ; Drug-Related Side Effects and Adverse Reactions ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Progression-Free Survival ; Receptor, ErbB-2/antagonists & inhibitors ; Response Evaluation Criteria in Solid Tumors ; Survival Rate ; United States
Czasopismo naukowe
Tytuł :
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
Autorzy :
Jackisch C; AGO-B and Sana Klinikum Offenbach GmbH, Offenbach, Germany. Electronic address: .
Cortazar P; Genentech, Inc., South San Francisco, CA, USA.
Geyer CE Jr; NSABP Foundation and Houston Methodist Cancer Center, Houston, TX, USA.
Gianni L; Ospedale San Raffaele, Milan, Italy.
Gligorov J; Institut Universitaire de Cancérologie, APHP-Sorbonne Université, Hôpital Tenon, Paris, France.
Machackova Z; Roche, Basel, Switzerland.
Perez EA; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Schneeweiss A; National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany.
Tolaney SM; Dana-Farber Cancer Institute, and Department of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA.
Untch M; AGO-B and HELIOS Klinikum Berlin Buch, Berlin, Germany.
Wardley A; Outreach Research & Innovation Group and Manchester Breast Centre, Division of Cancer Sciences and University of Manchester, Manchester, UK; AstraZeneca PLC, UK.
Piccart M; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Pokaż więcej
Źródło :
Cancer treatment reviews [Cancer Treat Rev] 2021 Sep; Vol. 99, pp. 102229. Date of Electronic Publication: 2021 May 20.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Decision Making*
Breast Neoplasms/*drug therapy
Breast Neoplasms/*surgery
Receptor, ErbB-2/*antagonists & inhibitors
Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Clinical Trials, Phase I as Topic ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Female ; Humans ; Lymphatic Metastasis ; Medical Oncology/standards ; Neoadjuvant Therapy ; Protein Kinase Inhibitors/administration & dosage ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2/metabolism ; Risk Factors
Czasopismo naukowe
Tytuł :
Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study.
Autorzy :
Yue M; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Zhang J; Tencent AI Lab, Nanshan District, Tencent Binhai Building, No. 33, Haitian Second Road, Shenzhen, 518054, Guangdong, China.
Wang X; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Yan K; Tencent AI Lab, Nanshan District, Tencent Binhai Building, No. 33, Haitian Second Road, Shenzhen, 518054, Guangdong, China.
Cai L; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Tian K; Tencent AI Lab, Nanshan District, Tencent Binhai Building, No. 33, Haitian Second Road, Shenzhen, 518054, Guangdong, China.
Niu S; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Han X; Tencent AI Lab, Nanshan District, Tencent Binhai Building, No. 33, Haitian Second Road, Shenzhen, 518054, Guangdong, China.
Yu Y; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Huang J; Tencent AI Lab, Nanshan District, Tencent Binhai Building, No. 33, Haitian Second Road, Shenzhen, 518054, Guangdong, China.
Han D; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Yao J; Tencent AI Lab, Nanshan District, Tencent Binhai Building, No. 33, Haitian Second Road, Shenzhen, 518054, Guangdong, China. .
Liu Y; Department of Pathology, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China. .
Pokaż więcej
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2021 Sep; Vol. 479 (3), pp. 443-449. Date of Electronic Publication: 2021 Jul 19.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Artificial Intelligence*
Image Interpretation, Computer-Assisted*
Immunohistochemistry*
Biomarkers, Tumor/*analysis
Breast Neoplasms/*chemistry
Carcinoma, Ductal, Breast/*chemistry
Microscopy/*instrumentation
Receptor, ErbB-2/*analysis
Automation, Laboratory ; Biomarkers, Tumor/genetics ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Carcinoma, Ductal, Breast/genetics ; Carcinoma, Ductal, Breast/pathology ; China ; Female ; Humans ; In Situ Hybridization, Fluorescence ; Observer Variation ; Predictive Value of Tests ; Receptor, ErbB-2/genetics ; Reproducibility of Results ; Retrospective Studies
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies